Sex-Specific Differences in Upstream Cardiac Damage in Patients With Aortic Stenosis Undergoing TAVR
JACC: Cardiovascular Interventions · 2024
DOI: 10.1016/j.jcin.2024.03.031 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von Masaaki Nakase und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: https://twitter.com/masaa…. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Registries, Health Status Disparities. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Cardiac damage caused by aortic stenosis (AS) can be categorized into stages, which are associated with a progressively increasing risk of death after transcatheter aortic valve replacement (TAVR). OBJECTIVES: The authors investigated sex-related differences in cardiac damage among patients with symptomatic AS and the prognostic value of cardiac damage classification in women and men undergoing TAVR. METHODS: In a prospective registry, pre-TAVR echocardiograms were used to categorize patients into 5 stages of cardiac damage caused by AS. Differences in the extent of cardiac damage were compared according to sex, and its implications on clinical outcomes after TAVR were explored. RESULTS: Among 2,026 patients undergoing TAVR between August 2007 and June 2022 (995 [49.1%] women and 1,031 [50.9%] men), we observed sex-specific differences in the pattern of cardiac damage (women vs men; stage 0: 2.6% vs 3.1%, stage 1: 13.4% vs 10.1%, stage 2: 37.1% vs 39.5%, stage 3: 27.5% vs 15.6%, and stage 4: 19.4% vs 31.7%). There was a stepwise increase in 5-year all-cause mortality according to stage in women (HRadjusted: 1.43; 95% CI: 1.28-1.60, for linear trend) and men (HRadjusted: 1.26; 95% CI: 1.14-1.38, for linear trend). Female sex was associated with a lower 5-year mortality in early stages (stage 0, 1, or 2) but not in advanced stages (stage 3 or 4). CONCLUSIONS: The pattern of cardiac damage secondary to AS differed by sex. In early stages of cardiac damage, women had a lower 5-year mortality than men, whereas in more advanced stages, mortality was comparable between sexes. (SwissTAVI Registry; NCT01368250).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: https://twitter.com/masaaki0825.
- Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Department of Cardiovascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: thomas.pilgrim@insel.ch.
Zitieren
APA
Nakase, M., Tomii, D., Maznyczka, A., Samim, D., Lanz, J., Praz, F., Stortecky, S., Reineke, D., Windecker, S., & Pilgrim, T. (2024). Sex-Specific Differences in Upstream Cardiac Damage in Patients With Aortic Stenosis Undergoing TAVR. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2024.03.031
Vancouver
Nakase M, Tomii D, Maznyczka A, Samim D, Lanz J, Praz F, et al. Sex-Specific Differences in Upstream Cardiac Damage in Patients With Aortic Stenosis Undergoing TAVR. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2024.03.031
BibTeX
@article{Nakase2024,
author = {Nakase, Masaaki and Tomii, Daijiro and Maznyczka, Annette and Samim, Daryoush and Lanz, Jonas and Praz, Fabien and Stortecky, Stefan and Reineke, David and Windecker, Stephan and Pilgrim, Thomas},
title = {Sex-Specific Differences in Upstream Cardiac Damage in Patients With Aortic Stenosis Undergoing TAVR},
journal = {JACC: Cardiovascular Interventions},
year = {2024},
doi = {10.1016/j.jcin.2024.03.031}
}
EUVIMED